- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02372162
Fingerprint Characterization of Advanced HCC (e:Med-HCC-1)
Fingerprint Characterization of Advanced HCC to Optimize Treatment Decisions and Enable an Early Prediction of Therapy Resistance (HCC Multiscale Trial-1)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A single-center, open-label, uncontrolled, non-randomized clinical trial. The two treatment groups to receive:
Group A Transarterial Chemoembolization (TACE): 20 patients that are treated with TACE will get an image and molecular fingerprint of the tumor prior to the first treatment with TACE, a second image fingerprint between week 2 - 4 after the first treatment with TACE, and a third image and molecular fingerprint at the time point of progressive disease.
Group B Sorafenib: 20 patients that are treated with Sorafenib will get an image and molecular fingerprint of the tumor prior to the first treatment, between week 2 and 3 after the start of treatment and at the time point of progressive disease.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
BW
-
Tuebingen, BW, Germany, D-72076
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients aged ≥ 18, of both genders, with advanced stage hepatocellular carcinoma, for Group A BCLC class B (intermediate stage, performance status-ECOG 0, multinodular HCC), for Group B BCLC class B or C (advanced stage, performance status-ECOG 1-2, invasive tumor pattern (vascular invasion/extra hepatic spread)).
Number: Up to 20 patients to receive therapy with TACE (Group A) and up to 20 patients to receive Sorafenib as first-line systemic therapy (Group B).
Description
Inclusion Criteria:
All inclusion criteria must be met at the time of screening unless otherwise specified:
- Male or female ≥ 18 years.
- Written informed consent obtained prior to any trial specific procedure.
- Advanced stage hepatocellular carcinoma, BCLC class B for Group A and BCLC class B or C for Group B (refer to Appendix 3 for BCLC classification).
- Child-Pugh class A and B. Only patients with Child-Pugh index class B of not more than 7 will be included. Patients with untreatable ascites or hepatic encephalopathy > Grade 1 are excluded (see exclusion criteria; (refer to Appendix 4 for Child Pugh classification)).
- Indication for TACE or sorafenib treatment confirmed by an interdisciplinary tumor board.
- ECOG performance status 0, 1 or 2 (refer to Appendix 2 for definitions of ECOG grades).
- Life expectancy of 12 weeks or more.
Adequate hematological parameters, as demonstrated by:
- Hemoglobin ≥ 9.0 g/dl (SI units: 5.6 mmol/l);
- WBC ≥ 3.0 x 109/l;
- Absolute neutrophil count ≥1,500/mm3;
- Platelets ≥ 75 x 109/l;
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 times upper limit of normal range (ULNR);
- Bilirubin ≤ 3 mg/dl;
- Serum creatinine ≤ 1.5 mg/dl (SI units: 132 µmol/l);
- Prothrombin Time (PT) International Normalized Ratio (INR) ≤ 1,5;
- Serum potassium, magnesium and calcium within normal range.
- Safe contraception in females of childbearing potential during the entire study using an established treatment with hormonal contraceptives for at least 2 months prior to start of screening.
- For females of child bearing potential (without using hormonal contraceptives for at least 2 months prior to start of screening) a double contraception method is requested during the entire study meeting the criteria for an effective method of birth control. That means at least two effective birth control methods such as condoms, diaphragms or intra-uterine devices must be used.
- Male patients with partners of child bearing potential are requested to use barrier contraception in addition to having their partner use another method of contraception during the trial and for 3 months after the last dose. Male patients will also be advised to abstain from sexual intercourse with pregnant or lactating women, or to use condoms.
- Able to comply with all the requirements of the protocol.
Exclusion Criteria:
Patients who meet any of the following criteria are not eligible for study participation:
- Renal failure requiring hemo- or peritoneal dialysis.
- Known central nervous system (CNS) tumors including symptomatic brain metastasis.
- Patients with no adequate treatment for gastrointestinal bleeding and esophagus varices within 14 days prior to study entry.
- Child-Pugh index class B in combination with more than slight ascites or hepatic encephalopathy > Grade I (see Child-Pugh index, Appendix 4).
- History and current cardiovascular complications, including unstable angina pectoris, uncontrolled hypertension, congestive heart failure (NYHA Class III or IV) related to primary cardiac disease, a condition requiring anti arrhythmic therapy, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to the trial entry.
- Current evidence of any severe internal, psychiatric or neurologic disease.
- Altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies.
- Pregnant or breastfeeding women.
- Active alcohol and/or drug abuse.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group A - TACE
Patients with transarterial chemoembolization (TACE) will get an "Image Fingerprint" and "Molecular Fingerprint" for tumor characterization in vivo.
|
This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
|
Group B - Sorafenib
Patients with Sorafenib treatment will get an "Image Fingerprint" and "Molecular Fingerprint" for tumor characterization in vivo.
|
This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Availability of comprehensive imaging and molecular fingerprint data of individual tumors
Time Frame: Each patient will be evaluated within six months, the whole study outcome will need 48 months
|
The aim of this feasibility study is to get comprehensive image and molecular fingerprints of individual tumors that can be used for systems biology approaches to predict therapy outcome and govern therapeutic decisions.
|
Each patient will be evaluated within six months, the whole study outcome will need 48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of turnaround time for image and molecular data availability
Time Frame: Each patient will be evaluated within six months, the whole study outcome will need 48 months
|
To set-up and optimize the workflow of data gathering and analysis for molecular and image fingerprints.
|
Each patient will be evaluated within six months, the whole study outcome will need 48 months
|
Description of correlations between image and molecular data
Time Frame: Each patient will be evaluated within six months, the whole study outcome will need 48 months
|
Correlation of results from image and molecular fingerprints at one point of time
|
Each patient will be evaluated within six months, the whole study outcome will need 48 months
|
Description of correlations between image and molecular data
Time Frame: Each patient will be evaluated within six months, the whole study outcome will need 48 months
|
Correlation of either image or molecular fingerprints at three different time points
|
Each patient will be evaluated within six months, the whole study outcome will need 48 months
|
Identification of molecular and image patterns of treatment failure
Time Frame: Each individual patient will be evaluated within six months, the whole study outcome will need 48 months
|
To identify molecular and image patterns of early treatment failure.
|
Each individual patient will be evaluated within six months, the whole study outcome will need 48 months
|
Identification of molecular and image patterns of treatment success
Time Frame: Each individual patient will be evaluated within six months, the whole study outcome will need 48 months
|
To identify molecular and image patterns of early treatment success
|
Each individual patient will be evaluated within six months, the whole study outcome will need 48 months
|
Comparison of molecular and image pattern fingerprints in patients and animal models
Time Frame: Evaluation within 48 months
|
To compare molecular and image patterns from HCC patients with respective patterns from different animal models which might identify suitable preclinical models for different clinical tumor patterns.
|
Evaluation within 48 months
|
Identification of early outcome prediction patterns
Time Frame: Evaluation within 48 months
|
To determine ideal imaging methods for an early prediction of progressive disease
|
Evaluation within 48 months
|
To provide data for a molecular diagnostic board
Time Frame: Each individual patient will be evaluated as soon as data sets are available within this feasibility study
|
To set up a molecular diagnostic board that checks for data-based tailored treatment options
|
Each individual patient will be evaluated as soon as data sets are available within this feasibility study
|
Biomarker analysis
Time Frame: Evaluation within 48 months
|
To identify clinical relevant biomarkers from tumor tissue or blood / urine analysis
|
Evaluation within 48 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Bitzer, MD, University Clinic, Eberhard Karls University, Tübingen, Germany
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- e:Med Tuebingen, Protocol #1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Hepatocellular
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on Image Fingerprint
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
-
Liverpool University Hospitals NHS Foundation TrustUniversity of LiverpoolCompletedComplication of Personal Oral HygieneUnited Kingdom
-
Deutsches Herzzentrum MuenchenUnknown
-
Philips Clinical & Medical Affairs GlobalCatharina Ziekenhuis EindhovenCompleted
-
Huashan HospitalUnknownGlioma | Anaplastic Oligoastrocytoma | Glioblastomas (GBM)
-
Seoul National University HospitalUnknownThoracic DiseasesKorea, Republic of
-
Norwegian School of Sport SciencesUniversity of Tromso; University of Agder; University College of Southeast Norway and other collaboratorsCompletedQuality of Life | Physical Activity | Eating BehaviorsNorway
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
-
Nantes University HospitalWithdrawnSymptomatic Aortic StenosisFrance